Lung cancer bone metastasis immunotherapy is the use of immune checkpoint inhibitors, such as nabumab and pembrolizumab, which can improve the efficiency of treatment.
Lung cancer is a kind of malignant tumor disease originated from the bronchial mucosa or glands in the lungs, and bone metastasis indicates that the disease has developed to an advanced stage, while immunotherapy is a method to treat advanced lung cancer. At present, immunotherapy for lung cancer bone metastasis mainly uses immune checkpoint inhibitors, which belongs to the first-line immunotherapy measures for advanced non-small cell lung cancer.
Clinically, PD-1 antibody and PD-L1 antibody are mainly used, and commonly used drugs include nabumab and pembrolizumab, etc., which help patients regulate the immune function of the body to a certain extent, and then can effectively improve the treatment efficiency as well as the overall survival period of patients. After immunotherapy, patients need to take bed rest and avoid strenuous exercise.
Patients with bone metastasis of lung cancer need to actively cooperate with doctors to carry out standardized treatment, strengthen daily life management, and go to the hospital for review on time to pay attention to the changes of their conditions.